Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma
- 4 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (6) , 1047-1057
Abstract
Background: Lifetime exposure to the varicella-zoster virus (VZV) has been consistently inversely associated with glioma risk, however, the relationship of VZV with survival in adults with glioma has not been investigated. In this study, we analyzed the survival of adults with glioma in relation to their antibody measurements to 4 common herpes viral infections, including VZV, measured post-diagnosis. Methods: We analyzed IgG antibody measurements to VZV, cytomegalovirus (CMV), herpes simplex virus 1/2 (HSV), and Epstein-Barr virus (EBV) collected from 1378 adults with glioma diagnosed between 1991 and 2010. Blood was obtained a median of 3 months after surgery. Associations of patient IgG levels with overall survival were estimated using Cox models adjusted for age, sex, self-reported race, surgery type, dexamethasone usage at blood draw, and tumor grade. Models were stratified by recruitment series and meta-analyzed to account for time-dependent treatment effects. Results: VZV antibody seropositivity was associated with improved survival outcomes in adults with glioma (Hazard ratio, HR = 0.70, 95% Confidence Interval 0.54–0.90, P = .006). Amongst cases who were seropositive for VZV antibodies, survival was significantly improved for those above the 25th percentile of continuous reactivity measurements versus those below (HR = 0.76, 0.66–0.88, P = .0003). Antibody seropositivity to EBV was separately associated with improved survival (HR = 0.71, 0.53–0.96, P = .028). Antibody positivity to 2 other common viruses (CMV, HSV) was not associated with altered survival. Conclusions: Low levels of VZV or EBV antibodies are associated with poorer survival outcomes for adults with glioma. Differential immune response rather than viral exposure may explain these findings.Keywords
Funding Information
- National Institutes of Health (T32CA151022, T32CA112355, R01CA52689, P50CA097257, R01CA126831, R01CA139020, R01CA266676)
- National Brain Tumor Foundation
- National Center for Advancing Translational Sciences (UL1 RR024131)
This publication has 46 references indexed in Scilit:
- Consensus on the role of human cytomegalovirus in glioblastomaNeuro-Oncology, 2012
- The roles of viruses in brain tumor initiation and oncomodulationJournal of Neuro-Oncology, 2011
- HCMV-Encoded Chemokine Receptor US28 Mediates Proliferative Signaling Through the IL-6–STAT3 AxisScience Signaling, 2010
- Glioma cancer stem cells induce immunosuppressive macrophages/microgliaNeuro-Oncology, 2010
- Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibilityNature Genetics, 2009
- Detection of human cytomegalovirus in different histological types of gliomasActa Neuropathologica, 2008
- Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma SurvivalCancer Research, 2006
- Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma modelNeuro-Oncology, 2005
- Human Papovavirus (JC): Induction of Brain Tumors in HamstersScience, 1973
- VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMAThe Lancet, 1964